Company profile
Medicenna Therapeutics Corp.
OTC: MDNAF · Healthcare · Biotechnology
Canadian filerHQ Toronto, ONCIK 0001807983Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 45
v0.1 · 5/100 weight · pillars only
↑ balance-sheet leverage, return on assets · ↓ workforce scale, listing tenure
Methodology →Revenue TTM
—
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$7.6M
Employees
20
as of 2026-09-08
Market cap
$26.9M
as of 2026-09-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$7.6M-10.0M CAD2023
Total assets$26.9M36.4M CAD2023
Liabilities$5.1M7.0M CAD2023
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Medicenna Therapeutics Corp.’s financial profile?
Medicenna Therapeutics Corp. earned -$7.6M in FY2023 net income.
Peers · Healthcare
Cell Source, Inc.——Vicapsys Life Sciences, Inc.——LeonaBio, Inc.——Lantern Pharma Inc.——Actuate Therapeutics Inc——Quantum BioPharma Ltd.——Key facts
CEOFahar Merchant
SectorHealthcare
IndustryBiotechnology
HeadquartersToronto, ON
ExchangeOTC: MDNAF
Employees20
IPO date2017-11-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.